MetabolicSURVODUTIDE
10MG
$110
Description
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim that combines the appetite-suppressing effects of GLP-1 receptor activation with the energy expenditure-boosting effects of glucagon receptor activation. While GLP-1 agonists reduce food intake and slow gastric emptying, the glucagon component uniquely promotes hepatic fat oxidation, increases energy expenditure, and improves lipid profiles. This dual mechanism makes survodutide particularly promising for research into metabolic conditions where liver fat accumulation is a key factor, such as non-alcoholic steatohepatitis (NASH).
Potential Benefits
Research Notes
Phase 2 clinical trial results published in The Lancet demonstrated survodutide's significant efficacy in both weight management (up to 18.7% body weight reduction at 46 weeks) and liver fat reduction. The ACHIEVE trial program for NASH showed substantial improvements in liver histology. Survodutide's glucagon receptor activity provides a mechanism for liver fat reduction that pure GLP-1 agonists lack, positioning it uniquely in metabolic research.
Usage Information
For research and educational purposes only. Consult with a qualified professional before use.
All peptides must be refrigerated upon receipt.
RESEARCH PURPOSES ONLY
This product is intended for research and educational purposes only. Not intended for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.